Retatrutide reported larger average weight loss than tirzepatide in phase 3 trials, but it is not an available treatment. In TRIUMPH-1, retatrutide 12mg was reported to produce 28.3% mean weight reduction at 80 weeks; tirzepatide produced 20.2% at 72 weeks in the peer-reviewed head-to-head SURMOUNT-5 trial. Tirzepatide is FDA-approved and prescribable today. Retatrutide is investigational: Eli Lilly stated in July 2026 that it plans to submit a Biologics License Application in the first quarter of 2027, which places any possible approval in late 2027 at the earliest, if the FDA grants it. Retatrutide cannot legally be prescribed, compounded, or purchased. This article summarizes published trial data and regulatory status as of October 2026; it is educational and is not medical advice or a recommendation to use any product. Advanced TRT Clinic is not affiliated with or endorsed by Eli Lilly or Novo Nordisk.
Where Each Molecule Stands Today
This comparison differs from most drug comparisons in one decisive way: only one of these two medications exists as a treatment option. Everything that follows should be read with that in mind.
Tirzepatide is a dual GIP and GLP-1 receptor agonist from Eli Lilly, approved as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in November 2023, with a later indication for obstructive sleep apnea in adults with obesity. It is prescribed by licensed clinicians, dispensed by licensed pharmacies, and covered by some insurance plans. Its safety profile has been characterized across a large approved-use population.
Retatrutide is an investigational triple GIP, GLP-1, and glucagon receptor agonist, also from Lilly, carrying the development code LY3437943. Its phase 3 TRIUMPH program has reported across four core trials. Lilly announced on 23 July 2026 that it plans to submit a Biologics License Application to the FDA in the first quarter of 2027. FDA review of a BLA typically takes ten to twelve months, which places any possible approval in late 2027 or 2028. Approval is the FDA’s decision and is never guaranteed. Until and unless it is granted, retatrutide is legally available only to participants in Lilly-sponsored clinical trials.
Any product sold to consumers as retatrutide — including anything labeled as a research peptide, research chemical, or “not for human use” — is outside the legal supply chain. There is no way to verify its identity, purity, sterility, or dose.
Eli Lilly has stated publicly that anything sold as retatrutide outside its clinical trials is illegal and that it works with law enforcement and regulators on the issue. Advanced TRT Clinic does not prescribe, supply, source, or facilitate access to retatrutide or to any other investigational product, and does not enroll patients in or arrange participation in clinical trials. Clinicians working through this platform prescribe only FDA-approved medications within their licensed scope of practice.
Mechanism: Two Receptors Versus Three
Both molecules are single engineered peptides built to activate more than one incretin receptor. The difference is what the third target adds.
Tirzepatide activates the GLP-1 receptor, which slows gastric emptying and suppresses appetite through hypothalamic signaling, and the GIP receptor, which improves insulin sensitivity in adipose tissue and appears to amplify the hypothalamic response to GLP-1 rather than duplicate it. Both mechanisms work on the intake side of the energy balance equation: patients eat less.
Retatrutide adds glucagon receptor agonism. This is a different kind of lever. Glucagon receptor activation increases energy expenditure and promotes hepatic lipolysis — it acts on the output side rather than the intake side. The proposed rationale for triple agonism is that combining reduced intake with increased expenditure may produce more weight loss than either alone, and the reported phase 3 figures are consistent with that hypothesis.
The same mechanism raises questions that only long-term data can settle. Glucagon raises hepatic glucose output, which is why attention to glycemic control in diabetic populations and dose-dependent heart rate changes have been part of the retatrutide safety discussion since the peer-reviewed phase 2 trial. Whether the added expenditure benefit holds up over years, and at what cost, is what the ongoing outcomes trial is designed to examine.
Mean Weight Reduction Reported Across Phase 3 Trials
Separate trials with different populations and durations — see the note below on why these are not a direct comparison
| RETATRUTIDE — INVESTIGATIONAL, SPONSOR TOPLINE DATA | ||||
| 12mg, TRIUMPH-1, 80 wk |
|
28.3% | ||
| 9mg, TRIUMPH-1, 80 wk |
|
25.9% | ||
| 12mg, TRIUMPH-3 (with CVD) |
|
22.6% | ||
| 12mg, TRIUMPH-2 (with T2D) |
|
20.8% | ||
| 4mg, TRIUMPH-1, 80 wk |
|
19.0% | ||
| TIRZEPATIDE — FDA-APPROVED, PEER-REVIEWED DATA | ||||
| 15mg, SURMOUNT-1, 72 wk |
|
20.9% | ||
| SURMOUNT-5, 72 wk |
|
20.2% | ||
| PLACEBO ARM, FOR SCALE | ||||
| TRIUMPH-1 placebo, 80 wk |
|
2.2% | ||
Figure 1. Bar widths are proportional to reported mean values. Retatrutide figures come from sponsor topline announcements and may be revised on full peer-reviewed publication. Populations, durations, and protocols differ between programs. These are group averages, not individual predictions — results vary and no outcome is guaranteed.
The Weight Loss Data Side by Side
The TRIUMPH program reported across four core registrational trials, each in a different population. The table below pairs them with the corresponding tirzepatide evidence, and marks which figures have completed peer review.
| Population | Retatrutide (investigational) | Tirzepatide (FDA-approved) |
|---|---|---|
| Obesity without diabetes | 28.3% at 12mg, 80 weeks (TRIUMPH-1, 2,339 participants; sponsor topline, May 2026) | 20.9% at 15mg, 72 weeks (SURMOUNT-1, peer-reviewed) |
| Obesity with type 2 diabetes | 20.8% at 12mg (TRIUMPH-2; sponsor topline, July 2026) | Approved for type 2 diabetes as Mounjaro; SURPASS program, peer-reviewed |
| Obesity with cardiovascular disease | 22.6% at 12mg, 80 weeks (TRIUMPH-3, 1,949 participants; sponsor topline, July 2026) | SURPASS-CVOT reported non-inferiority to dulaglutide in T2D with established cardiovascular disease; published December 2025 |
| Obesity with knee osteoarthritis | 28.7% at 12mg, 68 weeks, with reported WOMAC pain reduction (TRIUMPH-4; sponsor topline, December 2025) | No dedicated osteoarthritis trial reported |
| Extended treatment | 30.3% at 104 weeks in a BMI ≥35 extension cohort (sponsor topline) | SURMOUNT-4 assessed continued treatment versus withdrawal |
| Deep responders (≥25% loss) | 62.5% of participants at 12mg versus 2.2% on placebo (sponsor topline) | Reported in SURMOUNT-5 at a lower proportion |
| Head-to-head against semaglutide | None conducted | 20.2% vs 13.7% at 72 weeks (SURMOUNT-5, peer-reviewed) |
No randomized comparison exists. No trial has assigned participants to retatrutide versus tirzepatide. Every pairing above draws on separate programs run years apart, with different entry criteria and different placebo-arm performance.
Durations and baselines differ. TRIUMPH-1 ran 80 weeks against SURMOUNT-1’s 72, and weight loss curves in this class had not fully plateaued at either point. TRIUMPH-1 also enrolled a mean BMI of 40.0, and higher baseline weight tends to produce larger percentage reductions.
The retatrutide data have not completed peer review. The phase 3 figures above come from sponsor announcements. Topline numbers are sometimes revised when the full dataset, statistical methods, and adverse event tables are published and independently reviewed.
What can fairly be said is that the reported retatrutide figures are the largest published for any weight loss medication to date. What cannot be said is by how much the two molecules actually differ, because that has not been measured.
Safety and Tolerability: What Is Known and What Is Not
Adverse events reported with retatrutide in phase 3 were described as broadly consistent with other incretin-based therapies: nausea, diarrhea, vomiting, constipation, and reduced appetite were the most frequent, occurring more often than on placebo. This is the expected pattern for the drug class.
Two differences from tirzepatide matter. Discontinuation due to adverse events rose with dose in TRIUMPH-1 and was higher at the top dose than on placebo, which is consistent with a more potent agent. And glucagon receptor agonism introduces considerations that dual agonists do not have, because hepatic glucose output is directly affected and heart rate changes were observed in the peer-reviewed phase 2 data.
| Safety domain | Retatrutide | Tirzepatide |
|---|---|---|
| Gastrointestinal events | Most common adverse events; typical of the class | Characterized in detail across approved use |
| Cardiovascular outcomes | TRIUMPH-Outcomes ongoing; primary completion estimated 2029 | SURPASS-CVOT reported; non-inferior to dulaglutide in T2D with cardiovascular disease |
| Heart rate | Dose-dependent increases observed in phase 2; under continued evaluation | Modest increases described in approved labeling, as with the class |
| Boxed warning | Not yet established — no approved labeling exists | Thyroid C-cell tumors; MTC and MEN2 contraindicated |
| Long-term real-world data | None — no approved-use population exists | Accumulating since 2022 across a large prescribed population |
| Defined contraindications | Not yet defined — no approved labeling exists | Defined in approved labeling; includes MTC and MEN2 history |
Retatrutide has no boxed warning because it has no approved labeling, not because a risk has been ruled out. Boxed warnings are assigned at approval, based on the full data package the FDA reviews. Tirzepatide’s thyroid C-cell warning derives from rodent studies conducted on that molecule, and the corresponding labeling decision for retatrutide simply does not exist yet. Treating the absence of a warning as evidence of safety inverts how drug labeling works. For the established safety profile of the approved agent, see our complete guide to tirzepatide side effects.
What the Regulatory Gap Means in Practice
Patients following coverage of retatrutide’s trial results frequently ask whether it makes sense to wait. There is no general answer, because the relevant factors are individual and clinical. The table below sets out what is actually known on each side so that the question can be discussed with a clinician rather than settled from a headline.
Availability: Where Each Molecule Sits in the Regulatory Process
| TIRZEPATIDE — FDA-APPROVED | RETATRUTIDE — INVESTIGATIONAL |
|
Approved 2022 (Mounjaro) and 2023 (Zepbound) May be prescribed by a licensed clinician Dispensed by licensed US pharmacies Approved labeling with defined contraindications Manufacturer self-pay program available Some insurance coverage, varying by plan Cardiovascular outcomes trial reported |
Not approved by the FDA or any regulator BLA submission planned for Q1 2027 FDA review typically 10–12 months after filing Legal access only via Lilly clinical trials Cannot be prescribed or compounded No approved labeling or defined contraindications Outcomes trial completing around 2029 |
| On a standard review timeline and assuming approval is granted, the earliest availability for retatrutide would be late 2027 to 2028. |
Figure 2. Status as of October 2026. Regulatory timelines shift, and nothing here is a prediction of approval, which is the FDA’s decision alone.
What a clinician weighs when a patient raises this question
Several factors enter the discussion, and their relative weight differs from person to person. The current severity of the metabolic condition and whether it is progressing. Whether an approved therapy has already been tried, and with what result. Insurance coverage and out-of-pocket cost for an approved option today, against complete uncertainty about retatrutide’s eventual price, labeling, and coverage. Tolerability history. Comorbidities that make a particular receptor profile more or less suitable. And the patient’s own priorities, which may reasonably differ from a purely clinical calculation.
Two factual points belong in that conversation. First, the wait is not short: on a standard timeline it runs into 2028, and approval is not certain. Second, starting an approved therapy does not foreclose anything — patients change agents within this class routinely, and a future switch would be evaluated on its own merits at the time.
Advanced TRT Clinic provides administrative and technology services to a clinical practice that offers paid weight management services. That is a commercial interest, and readers should weigh this article accordingly. Nothing here is a recommendation to begin, continue, delay, or stop any treatment. Those decisions belong to you and a licensed clinician who has reviewed your medical history. For context on the full range of currently approved options, see our complete GLP-1 class overview and our comparison of tirzepatide versus semaglutide.
The Grey Market Problem
Retatrutide is unusual among investigational drugs in how widely it is sold illegally. The phase 2 data drew enough attention that vendors began offering vials labeled as retatrutide, typically described as research peptides or as material not intended for human use, long before phase 3 had reported.
The risks are not hypothetical or narrowly regulatory. There is no way to confirm that such a vial contains retatrutide, that the quantity matches the label, that it is sterile, or that it is free of contaminants. There is no approved dosing schedule to follow, because no approved product exists. There is no clinician overseeing escalation, no monitoring, and no recourse if something goes wrong. An adverse event has no reporting pathway and no manufacturer accountable for it.
Lilly’s TRIUMPH program trials are registered on ClinicalTrials.gov, and a pre-approval expanded access record has also been posted there. Eligibility criteria are strict and enrollment is limited. Anyone interested should raise it with their own treating physician, who can assess whether a registered study might apply to their situation. Advanced TRT Clinic does not enroll patients in clinical trials, does not refer to specific trial sites, and has no relationship with any trial sponsor. For what supervised therapy with an approved agent involves in practice, see our guide to safe use of tirzepatide.
Get a Physician Evaluation for GLP-1 Therapy
Advanced TRT Clinic provides administrative and technology services that connect patients with independent licensed clinicians through Beluga Health, P.A., who provide all clinical evaluation, treatment selection, prior authorization support, and ongoing monitoring. Clinicians work only with FDA-approved medications and can assess which currently available option, if any, fits your indication, comorbidities, and coverage. Advanced TRT Clinic does not prescribe, supply, or facilitate access to investigational or unapproved products, is not a pharmacy, does not fill prescriptions, and is not affiliated with, endorsed by, or a distributor for Eli Lilly or Novo Nordisk. No specific clinical outcome, insurance approval, or medication availability is guaranteed. All prescribing decisions are made by independent licensed clinicians based on individual patient assessment, within their scope of practice and applicable state law. Availability varies by state.
